On November 1, 2024, Thomas Sandgaard, President, CEO, Chairman, and 10% Owner of Zynex Inc (ZYXI, Financial), sold 6,000 shares of the company. Following this transaction, the insider now owns 14,621,350 shares of Zynex Inc. Details of the sale can be found in the SEC Filing.
Zynex Inc (ZYXI, Financial) is a company that specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring, and neurological diagnostics. These products aim to improve the quality of life for patients suffering from debilitating conditions.
Over the past year, Thomas Sandgaard has engaged in a total of 6,000 shares sold and has not purchased any shares. The insider transaction history for Zynex Inc shows a trend with 1 insider buy and 3 insider sells over the past year.
On the day of the recent transaction, shares of Zynex Inc were trading at $8.79, giving the company a market cap of $278.965 million. The price-earnings ratio stands at 62.57, which is significantly higher than both the industry median of 19.84 and the company’s historical median.
According to the GF Value, Zynex Inc has a price-to-GF-Value ratio of 0.67, indicating that the stock is significantly undervalued. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates.
This insider sale comes at a time when the stock is perceived as undervalued according to the GF Value, suggesting potential discrepancies between market prices and intrinsic values.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
